Sudo Biosciences
Healthcare & Life Sciences
Recent Finacing
Series B
Recent Raise
$116M
Sudo Biosciences is a biopharmaceutical company developing TYK2 inhibitor candidates for the treatment of multiple sclerosis, neurodegenerative, and immune-mediated dermatologic diseases.
Focus Areas
Biopharmaceuticals
TYK2 Inhibitors
Clinical Trials
Multiple Sclerosis
Neurodegenerative Diseases
Immune-Mediated Dermatologic Diseases
Investors
